Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT01745367. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Study Comparing Tivozanib Hydrochloride in Combination With Paclitaxel v Placebo in Combination With Paclitaxel in Locally Recurrent and/or Metastatic Triple Negative Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2 multicenter, double-blind, randomized, placebo-controlled, two-arm study for subjects with locally recurrent or metastatic triple negative breast cancer.
Study identification
- NCT ID
- NCT01745367
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2012 (Type not available)
- Primary completion
- Jun 2014 (Actual)
- Completion
- Jun 2014 (Actual)
- Last update posted
- Oct 27, 2020
2012 – 2014
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35005 | — |
| Not listed | Jacksonville | Florida | 32034 | — |
| Not listed | Miami | Florida | 33018 | — |
| Not listed | Atlanta | Georgia | 30301 | — |
| Not listed | Chicago | Illinois | 60007 | — |
| Not listed | Oak Lawn | Illinois | 60456 | — |
| Not listed | Fort Wayne | Indiana | 46774 | — |
| Not listed | Indianapolis | Indiana | 46077 | — |
| Not listed | Baltimore | Maryland | 21201 | — |
| Not listed | Boston | Massachusetts | 01841 | — |
| Not listed | St Louis | Missouri | 63101 | — |
| Not listed | New York | New York | 10001 | — |
| Not listed | The Bronx | New York | 10453 | — |
| Not listed | Chapel Hill | North Carolina | 27514 | — |
| Not listed | Fargo | North Dakota | 58102 | — |
| Not listed | Charleston | South Carolina | 02129 | — |
| Not listed | Sioux Falls | South Dakota | 57101 | — |
| Not listed | Memphis | Tennessee | 37501 | — |
| Not listed | Dallas | Texas | 75001 | — |
| Not listed | Galveston | Texas | 77550 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01745367, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2020 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01745367 live on ClinicalTrials.gov.